|
rs1057519816
|
|
Adenocarcinoma of lung (disorder)
|
|
0.710 |
GeneticVariation
|
BEFREE |
In this study, we reported the first clinical evidence of efficacy generated by afatinib, the irreversible HER family inhibitor, targeting HER2 S310Y single site mutation in lung adenocarcinoma.
|
29561699 |
2018 |
|
rs1057519816
|
|
Neoplasms
|
|
0.710 |
GeneticVariation
|
BEFREE |
The tumor was found to harbor both EGFR L858R and ERBB2 S310F alterations and also tested positive for a known TP53 germline mutation.
|
24835218 |
2014 |
|
rs1058808
|
|
Asthma
|
|
0.710 |
GeneticVariation
|
BEFREE |
ICSNPathway analysis identified four candidate causal SNPs, four genes, and 21 candidate causal pathways, which in total provided four hypothetical biologic mechanisms: (1) rs7192 (nonsynonymous coding) to HLA-DRA to 21 pathways, such as, the role of eosinophils in the chemokine network of allergy, Th1/Th2 differentiation, and asthma (nominal p ≤ 0.001, FDR p ≤ 0.01); (2) rs20541 (nonsynonymous coding) to IL13 to asthma and cytokines and inflammatory response (nominal p<0.001, FDR p ≤ 0.008); (3) rs1058808 (frameshift coding) to ERBB2 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01); (4) rs17350764 (nonsynonymous coding (deleterious)) to OR52J3 to transmembrane receptor activity (nominal p=0.001, FDR p=0.01).
|
23200760 |
2013 |
|
rs121913469
|
|
Carcinoma of lung
|
|
0.710 |
GeneticVariation
|
BEFREE |
Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
|
25620423 |
2015 |
|
rs28933369
|
|
Neoplasms
|
|
0.710 |
GeneticVariation
|
BEFREE |
In both spontaneous and DMBA studies, onset of palpable tumors was delayed in G60S mice compared with mice in control groups.
|
21151177 |
2011 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.
|
29417620 |
2018 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.
|
29417620 |
2018 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We studied the HER2 codon 655 (rs1136201) polymorphism in 80 Austrian patients with BC and 100 healthy volunteers by pyrosequencing and polymerase chain reaction.
|
26637882 |
2015 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
We studied the HER2 codon 655 (rs1136201) polymorphism in 80 Austrian patients with BC and 100 healthy volunteers by pyrosequencing and polymerase chain reaction.
|
26504013 |
2015 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We studied the HER2 codon 655 (rs1136201) polymorphism in 80 Austrian patients with BC and 100 healthy volunteers by pyrosequencing and polymerase chain reaction.
|
26504013 |
2015 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We studied the HER2 codon 655 (rs1136201) polymorphism in 80 Austrian patients with BC and 100 healthy volunteers by pyrosequencing and polymerase chain reaction.
|
26637882 |
2015 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, our meta-analysis findings suggest that the HER2 Ile655Val polymorphism is marginally associated with breast cancer susceptibility in worldwide populations with additive and dominant models, but not a recessive model.
|
25520082 |
2014 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, our meta-analysis findings suggest that the HER2 Ile655Val polymorphism is marginally associated with breast cancer susceptibility in worldwide populations with additive and dominant models, but not a recessive model.
|
25520082 |
2014 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
HER2 Ile655Val polymorphism was determined in 4167 patients with primary breast cancer using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.
|
24608202 |
2014 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
HER2 Ile655Val polymorphism affects the function of HER2 gene only restricted in HER2-positive breast cancers.
|
24608202 |
2014 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this case control study we aimed to analyze the frequency of HER1 R497K (rs 11543848) and HER2 I655V (rs 1136201) Polymorphisms in breast cancer.
|
23594562 |
2013 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis aimed to assess the association between ERBB2 Ile655Val and Ala1170Pro polymorphisms and the susceptibility to breast cancer.
|
23900832 |
2013 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Analysis on clinico-pathological parameters showed neither HER2 Ile655Val nor PTEN IVS4 genotypes were not associated with any of the variables (p > 0.05).In conclusion, our findings suggest that the Ile/Val genotype of HER2 and ATCTT insertion (+/+) genotype of PTEN IVS4 gene may play an important role as genetic markers for breast cancer risk, but both genes genotypes may not be useful for predicting tumor prognosis in Turkish population.
|
23086302 |
2013 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
Analysis on clinico-pathological parameters showed neither HER2 Ile655Val nor PTEN IVS4 genotypes were not associated with any of the variables (p > 0.05).In conclusion, our findings suggest that the Ile/Val genotype of HER2 and ATCTT insertion (+/+) genotype of PTEN IVS4 gene may play an important role as genetic markers for breast cancer risk, but both genes genotypes may not be useful for predicting tumor prognosis in Turkish population.
|
23086302 |
2013 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis aimed to assess the association between ERBB2 Ile655Val and Ala1170Pro polymorphisms and the susceptibility to breast cancer.
|
23900832 |
2013 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this case control study we aimed to analyze the frequency of HER1 R497K (rs 11543848) and HER2 I655V (rs 1136201) Polymorphisms in breast cancer.
|
23594562 |
2013 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is unlikely that HER2 rs1136201 is a risk factor for breast cancer.
|
21474413 |
2011 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer.
|
21204706 |
2011 |
|
rs1136201
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
One single-nucleotide polymorphism at codon 655 indicates a guanine-to-adenine substitution (Ile655Val) in the transmembrane domain-coding region of the HER-2/neu gene reported to be associated with increased risk of breast cancer.
|
21204706 |
2011 |
|
rs1136201
|
|
Malignant neoplasm of breast
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study was conducted to clarify the diagnostic and prognostic significance of TNF-alpha and its combination with HER-2 Ile655Val SNP in breast cancer.
|
20872355 |
2011 |